Cancer is a severe public health issue that is a leading cause of mortality globally. It is also
an impediment to improving life expectancy worldwide. Furthermore, the global burden of …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …

Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid
peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

Inactive state-selective KRAS (G12C) inhibitors,,,,,,–demonstrate a 30–40% response rate
and result in approximately 6-month median progression-free survival in patients with lung …

Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …

Patients with high-grade serous ovarian cancer suffer poor prognosis and variable response
to treatment. Known prognostic factors for this disease include homologous recombination …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …